

HOUSE BILL No. 4783

June 11, 1999, Introduced by Reps. Faunce, Van Woerkom, Kukuk, Rocca, Bisbee, Koetje, Vear and LaSata and referred to the Committee on Health Policy.

A bill to amend 1978 PA 368, entitled
"Public health code,"
by amending section 7216 (MCL 333.7216).

THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

1 Sec. 7216. (1) The following controlled substances are
2 included in schedule 3:
3 (a) Unless listed in another schedule, any material, com-
4 pound, mixture, or preparation CONTAINING ANY QUANTITY OF THE
5 FOLLOWING SUBSTANCES HAVING A POTENTIAL FOR ABUSE ASSOCIATED WITH
6 A STIMULANT EFFECT ON THE CENTRAL NERVOUS SYSTEM, including ~~its~~
7 THEIR salts, isomers, ~~(whether~~ INCLUDING optical, position, or
8 geometric ~~)~~ ISOMERS, and salts of the isomers ~~when~~ IF the
9 existence of the salts, isomers, and salts of isomers is possible
10 within the specific chemical designation: ~~as listed in schedule~~
11 ~~3, which contains any quantity of the following substances having~~

1 ~~a potential for abuse associated with a stimulant effect on the~~
 2 ~~central nervous system:~~

3

4	Benzphetamine	Mediatric tabs
5	Chlorphentermine	Mediatric liquid
6	Clortermine	Phendimetrazine
7	Edrisal tabs	Special formula 711 tabs
8	Genegestic caps	Thora Dex No. 1 tab
9	Hovizyme tabs	Thora Dex No. 2 tab
10	Mazindol	

11 (b) Unless listed in another schedule, any material, com-
 12 pound, mixture, or preparation CONTAINING ANY QUANTITY OF THE
 13 FOLLOWING SUBSTANCES HAVING A POTENTIAL FOR ABUSE ASSOCIATED WITH
 14 A DEPRESSANT EFFECT ON THE CENTRAL NERVOUS SYSTEM, including
 15 ~~its~~ THEIR salts, isomers, ~~(whether~~ INCLUDING optical, posi-
 16 tion, or geometric ~~)~~ ISOMERS, and salts of the isomers ~~when~~
 17 IF the existence of the salts, isomers, and salts of isomers is
 18 possible within the specific chemical designation: ~~as listed in~~
 19 ~~schedule 3, which contains any quantity of the following sub-~~
 20 ~~stances having a potential for abuse associated with a depressant~~
 21 ~~effect on the central nervous system:~~

22

23	Chlorhexadol	Phencyclidine
24	Glutethimide	Sulfondiethylmethane
25	Lysergic acid	Sulfonethylmethane
26	Lysergic acid amide	Sulfonmethane

1 Methyprylon

2 (c) Nalorphine.

3 (d) Any substance ~~which~~ THAT contains any quantity of a
4 derivative of barbituric acid, or any salt of a derivative of
5 barbituric acid, except those substances ~~which~~ THAT are specif-
6 ically listed in other schedules.

7 (e) A compound, mixture, or preparation containing amobarbi-
8 tal, secobarbital, pentobarbital, or ~~any~~ A salt ~~thereof~~ OF
9 AMOBARBITAL, SECOBARBITAL, OR PENTOBARBITAL, and 1 or more other
10 active medicinal ingredients ~~which~~ THAT are not listed in a
11 schedule.

12 (f) A suppository dosage form containing amobarbital, seco-
13 barbital, pentobarbital, or a salt of ~~any of these drugs~~
14 AMOBARBITAL, SECOBARBITAL, OR PENTOBARBITAL and approved by the
15 food and drug administration for marketing only as a
16 suppository.

17 (g) Any material, compound, mixture, or preparation contain-
18 ing limited quantities of any of the following narcotic drugs or
19 ~~any~~ THEIR salts: ~~thereof:~~

20 (i) Not more than 1.8 grams of codeine, or any of its salts,
21 per 100 milliliters or not more than 90 milligrams per dosage
22 unit, with an equal or greater quantity of an isoquinoline alka-
23 loid of opium.

24 (ii) Not more than 1.8 grams of codeine, or any of its
25 salts, per 100 milliliters or not more than 90 milligrams per
26 dosage unit, with 1 or more active ~~—~~ nonnarcotic ingredients in
27 recognized therapeutic amounts.

1 (iii) Not more than 300 milligrams of dihydrocodeinone, or
2 any of its salts, per 100 milliliters or not more than 15 milli-
3 grams per dosage unit, with a fourfold or greater quantity of an
4 isoquinoline alkaloid of opium.

5 (iv) Not more than 300 milligrams of dihydrocodeinone, or
6 any of its salts, per 100 milliliters or not more than 15 milli-
7 grams per dosage unit, with 1 or more active — nonnarcotic
8 ingredients in recognized therapeutic amounts.

9 (v) Not more than 1.8 grams of dihydrocodeine, or any of its
10 salts, per 100 milliliters or not more than 90 milligrams per
11 dosage unit, with 1 or more active nonnarcotic ingredients in
12 recognized therapeutic amounts.

13 (vi) Not more than 300 milligrams of ethylmorphine, or any
14 of its salts, per 100 milliliters or not more than 15 milligrams
15 per dosage unit, with 1 or more ingredients in recognized thera-
16 peutic amounts.

17 (vii) Not more than 500 milligrams of opium per 100 millili-
18 ters or per 100 grams, or not more than 25 milligrams per dosage
19 unit, with 1 or more active — nonnarcotic ingredients in recog-
20 nized therapeutic amounts.

21 (viii) Not more than 50 milligrams of morphine, or any of
22 its salts, per 100 milliliters or per 100 grams, with 1 or more
23 active — nonnarcotic ingredients in recognized therapeutic
24 amounts.

25 (H) ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION CONTAIN-
26 ING ANY QUANTITY OF KETAMINE, A SALT OF KETAMINE, AN ISOMER OF
27 KETAMINE, OR A SALT OF AN ISOMER OF KETAMINE.

1 (I) GAMMA-BUTYROLACTONE.

2 (2) The administrator may promulgate rules to except a com-
3 pound, mixture, or preparation containing any stimulant or
4 depressant substance listed in subsection (1)(a) and (b) from the
5 application of all or any part of this article if the compound,
6 mixture, or preparation contains 1 or more active medicinal
7 ingredients not having a stimulant or depressant effect on the
8 central nervous system ~~—~~ and if the admixtures are ~~included~~
9 ~~therein~~ in combinations, quantity, proportion, or concentration
10 that vitiate the potential for abuse of the substances ~~—which~~
11 ~~have~~ HAVING a stimulant or depressant effect on the central ner-
12 vous system.